Apixaban and Desvenlafaxine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Desvenlafaxine
Apixaban
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed two medicines that can each make bleeding a little more likely. Apixaban (Eliquis) is a blood thinner, and desvenlafaxine (Pristiq) is an antidepressant that can affect how your blood platelets clump together. Taken together, they can add up and raise your chance of bleeding.
This doesn't mean you can't take both. Many people do safely. Just watch for signs like unusual bruising, nosebleeds that won't stop, blood in your urine or stool, black stools, or bleeding that won't quit. If you notice anything serious, get help right away. Your care team can manage this by keeping an eye on you, and they're your best resource if you have questions.
Effect: Additive pharmacodynamic increase in bleeding risk when apixaban (factor Xa inhibitor) is combined with an SNRI. SNRIs impair serotonin-mediated platelet aggregation, compounding apixaban's anticoagulant effect.
- Direction: Increased bleeding risk (additive on hemostasis, not a PK/CYP interaction).
- Severity/Evidence: Major severity; substantiation is theoretical.
- Onset: Unspecified; apixaban's PD effect persists at least 24 hours after last dose.
- Management: Counsel on bleeding signs; discontinue apixaban for active pathological hemorrhage. A specific anti-FXa reversal agent (andexanet alfa) exists; PCC, aPCC, or rFVIIa may be considered. Clotting assays are not useful to guide PCC use.
What happens
An increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Giving apixaban, a factor Xa inhibitor, together with other agents that influence hemostasis, for example an SNRI, may raise the likelihood of bleeding. If active pathological bleeding develops, apixaban should be stopped. There is an agent that reverses the anti-factor Xa activity of apixaban. Apixaban's pharmacodynamic effect is anticipated to remain for a minimum of 24 hours following the final dose. Patients should be counseled about the signs and symptoms of blood loss and instructed to report them without delay or to present to an emergency room. In patients experiencing active pathological hemorrhage, apixaban should be discontinued. An agent to reverse apixaban's anti-factor Xa activity is available. The drug's pharmacodynamic effect can be expected to last for at least 24 hours after the last dose. Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. In cases where PCCs are given, tracking apixaban's anticoagulant effect by means of a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity provides no benefit and is not advised. Activated oral charcoal decreases the absorption of apixaban, which in turn lowers its plasma concentration1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
The goal is to use both medicines safely while staying alert for bleeding.
- Keep taking both as prescribed unless your doctor tells you otherwise. Do not stop either on your own.
- Know the warning signs: unusual or heavy bruising, nosebleeds, bleeding gums, pink or red urine, black or bloody stools, coughing or vomiting blood, or any bleeding that won't stop.
- Report bleeding immediately or go to an emergency room if it is serious.
- Your care team may monitor you more closely, and there is a reversal agent available for apixaban if a serious bleed occurs.
- Tell your pharmacist about any new medicines, including over-the-counter pain relievers like aspirin or ibuprofen.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Apixaban and Desvenlafaxine together?
Combining apixaban (Eliquis) and desvenlafaxine (Pristiq) can add up to raise bleeding risk, so watch for signs of bleeding and get medical help right away if serious bleeding occurs. Keep taking both as prescribed and let your care team manage and monitor this. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Apixaban and Desvenlafaxine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Apixaban and Desvenlafaxine interaction managed?
The goal is to use both medicines safely while staying alert for bleeding. Keep taking both as prescribed unless your doctor tells you otherwise. Do not stop either on your own. Know the warning signs: unusual or heavy bruising, nosebleeds, bleeding gums, pink or red urine, black or bloody stools, coughing or vomiting blood, or any bleeding that won't stop. Report bleeding immediately or go to an… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Apixaban or Desvenlafaxine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
Keep reading about Desvenlafaxine
Keep reading about Apixaban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist